1.
Br J Dermatol
; 179(6): 1392-1395, 2018 12.
Article
in English
| MEDLINE
| ID: mdl-29663331
ABSTRACT
Cutaneous angiosarcoma (CAS) is a highly aggressive vascular tumour that recurs locally and metastasizes early. Although chemoradiotherapy with taxanes shows a high response rate with prolonged survival, second-line therapy for advanced CAS remains contentious. This report describes three patients with advanced CAS treated with eribulin. In addition, we investigated serum soluble (s)CD163, chemokine (C-X-C motif) ligand 10 (CXCL10) and chemokine (C-C motif) ligand 2 levels at several time points of tumour progression in these patients, revealing serum levels of sCD163 and CXCL10 as potential biomarkers for progression of CAS.
Subject(s)
Antigens, CD/blood , Antigens, Differentiation, Myelomonocytic/blood , Biomarkers, Tumor/blood , Chemokine CXCL10/blood , Furans/administration & dosage , Hemangiosarcoma/therapy , Ketones/administration & dosage , Receptors, Cell Surface/blood , Skin Neoplasms/therapy , Aged , Chemoradiotherapy/methods , Disease Progression , Dose Fractionation, Radiation , Drug Administration Schedule , Fatal Outcome , Female , Hemangiosarcoma/blood , Hemangiosarcoma/pathology , Humans , Male , Neoplasm Staging , Predictive Value of Tests , Prognosis , Radiosurgery , Skin/drug effects , Skin/pathology , Skin/radiation effects , Skin Neoplasms/blood , Skin Neoplasms/pathology , Treatment Outcome
2.
Br J Dermatol
; 185(6): 1267-1269, 2021 12.
Article
in English
| MEDLINE
| ID: mdl-34254294
3.
Br J Dermatol
; 182(5): 1297-1300, 2020 05.
Article
in English
| MEDLINE
| ID: mdl-31746456
4.
Hokenfu Zasshi
; 33(4): 243-50, 1977 Apr.
Article
in Japanese
| MEDLINE
| ID: mdl-584873